Skip to main content
. 2019 Oct 15;8(11):60. doi: 10.1038/s41389-019-0170-y

Fig. 6. HOXA-AS3 deletion decreased cisplatin resistance via upregulating HOXA3.

Fig. 6

ad CCK-8 assay of the viability of NSCLC cell lines following cisplatin treatment (0, 1.049, 2.097, 4.195, 8.389, 16.779 μM) under HOXA-AS3 + HOXA3, or HOXA-AS3 only suppression for 48 h. (*p < 0.05, **p < 0.01, ***p < 0.001)